Sandoz Agrees to $478.5 Million Settlement Over Generic Drug Price-Fixing Allegations

The settlement resolves claims from dozens of U.S. states and medicine resellers who alleged the company reduced competition to harm consumers.

The financial agreement is split into three distinct payments. Sandoz will pay $400 million over seven years, beginning in 2027, to resolve remaining claims by U.S. states in three pending cases. The company will also make a payment of approximately $50 million to states that reached settlements earlier, and $28.5 million to resolve class-action litigation brought by indirect resellers, STAT reported.

Sandoz did not admit to any wrongdoing as part of the agreement, according to the source.

Generic Drug Price-Fixing Litigation

This settlement is part of a broader, long-running legal battle involving multiple major players in the generic pharmaceutical industry. According to STAT, these companies faced accusations of fixing prices for their medicines to maintain high costs and limit market competition.

Other industry participants have reached similar agreements to resolve lawsuits. STAT noted that Glenmark Pharmaceuticals, Lannett, Bausch, Apotex, and Heritage Pharmaceuticals collectively settled lawsuits for nearly $98 million.

Impact on Drug Pricing and Competition

The allegations centered on a widespread conspiracy to manipulate the cost of generic medications. By artificially inflating prices and reducing competition, the plaintiffs argued that consumers were forced to pay more for essential medicines than they would have in a competitive market.

Generic drugs are typically intended to provide a lower-cost alternative to brand-name pharmaceuticals. When companies engage in price-fixing, the cost-saving benefit of generics is diminished, which can affect public health access and the overall cost of healthcare delivery.